NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Medical Devices · USD

Integra LifeSciences Holdings Corporation (IART) Stock Analysis

Integra LifeSciences Holdings Corporation (IART) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

IART

$11.84

−$1.49 (−11.18%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare IART with… →

IART Key Statistics

As of Oct 21, 2026
Trading
Open
$12.78
Previous Close
$13.33
Day's Range
11.57–13.75
52-Week Range
8.70–20.49
Volume
2.02M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.21
Valuation
Market Cap
$920.83M
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
4.78
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
0.67
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.56
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.09
Financials (FY)
Revenue (FY)
$1.64B+1.53%
Net Income (FY)
−$516.47M
Profit marginThe share of revenue left as profit after all costs and taxes.
−0.44%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
77.77M
1-Year Return
−25.44%
Dividend and dates
Earnings Date
October 21, 2026
Avg Volume
930.38K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, IART closed at $11.84, −25.44% over 1 year.

Integra LifeSciences Holdings Corporation (IART) has a market capitalization of $920.83M.

In fiscal 2025, IART reported revenue of $1.64B.

IART Stock Return by Calendar Year

Integra LifeSciences Holdings Corporation (IART) 10-year return: what $10,000 became

1 year
$10,000 $7,456
−25.44%
5 years
$10,000 $1,669
−83.31%
10 years
$10,000 $2,907
−70.93%

If you had invested $10,000 in Integra LifeSciences Holdings Corporation (IART) 10 years ago, at the close on October 21, 2016, it would have been worth $2,907 at the close on October 21, 2026: −70.93% in total, −11.62% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−4.67%
2025−45.24%
2024−47.92%
2023−22.33%
2022−16.30%
2021+3.19%
2020+11.39%
2019+29.22%
2018−5.77%
2017+11.57%
2016 (partial year)+2.02%

As of October 21, 2026.

IART Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$1.64B−$516.47M−31.6%
2024$1.61B−$6.94M−0.4%
2023$1.54B$67.74M4.4%
2022$1.56B$180.55M11.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$1.64B$831.62M$18.00M−$516.47M−31.6%
2024$1.61B$882.06M$28.41M−$6.94M−0.4%
2023$1.54B$884.74M$111.53M$67.74M4.4%
2022$1.56B$970.31M$238.92M$180.55M11.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

IART Valuation vs Medical Devices Median

Median of 145 stocks
MetricIARTMedical Devices medianvs median
P/S ratio0.562.530.2x the median
Profit margin−0.44%−14.78%14.3 pts above

Medians across 145 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Integra LifeSciences Holdings Corporation (IART) carries a market capitalisation of $920.83M. The company sits in the Healthcare sector, in the Medical Devices industry. Headcount on file is 4,427.

The most recent close on file for IART is $11.84, dated October 21, 2026. That is −$1.49 (−11.18%) against the previous close. Over the past 52 weeks the price has ranged from $8.70 to $20.49. The latest close sits 36.09% above that 52-week low.

Financial Health

In fiscal 2025, Integra LifeSciences Holdings Corporation reported revenue of $1.64B. Against the prior fiscal year total of $1.61B, that is a change of +1.53%. The same year closed with a net loss of $516.47M. Profit margin runs at −0.44%. That is 14.3 percentage points above the Medical Devices median of −14.78%. Earnings per share on a trailing basis come to −0.09.

Across the 4 fiscal years on file, revenue moves from $1.56B in 2022 to $1.64B in 2025. Of those 4 years, 2 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The forward P/E on file is 4.78. The PEG ratio, which sets the P/E against expected earnings growth, reads 0.67. The price-to-sales ratio is 0.56. On price-to-sales that is 0.2 times the Medical Devices median of 2.53. The medians here are taken across 145 Medical Devices companies that report the metric.

The reported beta is 1.21. Annualized volatility over the trailing 10 years is 41.47%. Over the trailing twelve months the total return is −25.44%. Across 10 years the annualized return works out at −11.62%.

Growth & Income

The record shows no dividend for IART.

The strongest complete calendar year on file is 2019 at +29.22%; the weakest is 2024 at −47.92%. Of the 9 complete calendar years on file, 4 finished higher. So far in 2026 the total return is −4.67%.

Peer Comparison

Integra LifeSciences Holdings Corporation (IART) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Integra LifeSciences Holdings Corporation IART $920.83M —
Abbott Laboratories ABT $173.92B 32.4
Medtronic plc. MDT $119.00B 22.9
Stryker Corporation SYK $114.15B 30.8

The Medical Devices industry average P/E ratio is 27.1x. Integra LifeSciences Holdings Corporation has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$173.92B

 MDT

Medtronic plc.

$119.00B

 SYK

Stryker Corporation

$114.15B

 BSX

Boston Scientific Corporation

$64.33B

 EW

Edwards Lifesciences Corporation

$50.95B

 GEHC

GE HealthCare Technologies Inc.

$31.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Integra LifeSciences Holdings Corporation

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. It also offers after-market services; surgical headlamps and instrumentation; instrument patterns and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices. In addition, the company provides treatment of acute wounds, such as burns; chronic wounds, including diabetic foot ulcers; and surgical tissue repair applications, including hernia reinforcement, tendon protection, and peripheral nerve repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, and nerve and tendon repair products. Additionally, the company is involved in the ear, nose, and throat business that includes instrumentation, balloon technologies for sinus dilation and eustachian tube dilation, and surgical navigation systems. It offers its products directly through various salesforces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, the Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was formerly known as Integra LifeSciences Corp. and changed its name to Integra LifeSciences Holdings Corporation in June 1995. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

Visit website →